Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device avoids mechanical moving components and makes use of the body’s own peristaltic forces to facilitate the delivery of the biologic efficiently into the gastrointestinal wall. The team behind Biograil is a combination of seasoned entrepreneurs with long experience in creating successful biotech companies as well as R&D executives behind the world’s first injection molded oral tablet to be approved by the FDA.

Press releases

Biograil secures seed funding for oral delivery device with potential to transform market for injectables

Biograil ApS, an innovative biotechnology company developing a unique oral device for delivery of biologics that would otherwise be injected, today announced the closing of a seed funding of 3 Million Euro (with potential to expand to 5 Million Euro). The investor Syndicate was…

Info & Contact

Karsten Lindhardt (CEO)
+45 21 66 39 41


Biograil ApS
Baldersbuen 2
2640 Hedehusene

In portfolio

20. Dec 2019